|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Sno | WO Number | Year of Filing | Formula | Claims | Diseases | Compounds |
| 41 | **US20210380525** | 2021 |  | A compound of Formula I    wherein  R 1and R 2independently represent CD 3, CH 3, H, D, CD 3CO—, NULL,    R 3and R 5independently represent CD 3, CH 3, H, D, CD 3CO—, NULL,      n is independently 1, 2, 3, 4, 5 or 6;  m is independently 1 to 13;  a is independently 2, 3 or 7;  each b is independently 3, 5 or 6;  e is independently 1, 2 or 6;  c and d are each independently H, D, —OH, —OD, C 1-C 6-alkyl, —NH 2or —COCH 3;  within proviso,  R 7and R 8independently represent CD3, CH3, H, D, CD3CO—, NULL,    2. (canceled)  3. (canceled)  4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  5. (canceled)  6. (canceled)  7. The pharmaceutical composition of claim 4, wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount of said pharmaceutical composition by oral administration, systemic administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, subcutaneous, intramuscular administration, intravenous administration, intranasal administration, intramedullary administration, oral solution, rectal administration, buccal administration, or transdermal administration.  8. (canceled)  9. (canceled)  10. The pharmaceutical composition of claim 7, wherein said pharmaceutical composition is formulated for the treatment of Parkinson's disease, scleroderma, restless leg syndrome, hypertension or gestational hypertension.  11. (canceled)  12. (canceled)  13. A compound of claim 1, wherein said compound is selected from a group consisting of:     |  | | --- | | **14**. A pharmaceutical composition comprising a compound of [**claim 13**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US344363431&_cid=P12-L9KP4E-85999-5#CLM-00013) and a pharmaceutically acceptable carrier. | | **15**. The pharmaceutical composition of [**claim 14**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US344363431&_cid=P12-L9KP4E-85999-5#CLM-00014), wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount of said pharmaceutical composition by oral administration, systemic administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, subcutaneous, intramuscular administration, intravenous administration, intranasal administration, intramedullary administration, oral solution, rectal administration, buccal administration, or transdermal administration. | | **16**. The pharmaceutical composition of [**claim 15**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US344363431&_cid=P12-L9KP4E-85999-5#CLM-00015), wherein said pharmaceutical composition is formulated for the treatment of Parkinson's disease, scleroderma, restless leg syndrome, hypertension or gestational hypertension. | | treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. |  |
| 42 | **WO2021245503** | 2021 |  | We claim:  1. A process for preparing 2-Amino-2-(difluoromethyl)-5-(2-propylpentanamido) pentanoic acid or pharmaceutically acceptable salts, polymorphs, stereoisomers, enantiomers thereof.  2. The process of claim 1, wherein preparing 2-Amino-2-(difluoromethyl)-5-(2- propylpentanamido) pentanoic acid hydrochloride or a pharmaceutically acceptable polymorphs, stereoisomers, enantiomers thereof, comprising synthesis of 2-Propylpentanoyl Chloride and reacting the 2-Propylpentanoyl Chloride with Eflornithine HC1 in 5N Ag NaOH.  3. The process of claim 2, wherein the reaction takes place in a polar or a non-polar solvents or mixtures thereof, selected from the group consisting of acetone, acetic acid, ethyl methyl ketone, methyl isobutyl ketone, isopropanol, acetonitrile, ammonia (aqueous), n-amyl acetate, amyl alcohol, aniline, benzene, 2-butanone (MEK), n-butyl acetate, n-butyl alcohol, methanol, ethanol, propanol, n-propanol, 1- butanol, 2-butanol, tert -butyl alcohol, 2-butanone, pentane, formic acid, hexane, heptane, carbon tetrachloride, carbon disulfide, chlorobenzene, chloroform, chloromethene, diethylamine, cyclohexane, o-dichlorobenzene (1,2- Dichlorobenzene), 1,2-dichloroethane, diethyelene glycol, diethyl ether, N,N-dimethyl acetamide, ethylene glycol, p-xylene, toluene, N,N-dimethylaniline, Ethyl Acetate Ethanol, ethyl acetate, 1,4-Dioxane, acetonitrile, water, heavy water or mixtures thereof in any proportion.  4. The process of claim 3, wherein the solvent is selected from dichloro methane methanol, acetone, acetonitrile or a mixture thereof.  5. The process of claim 2, wherein the 2-Propylpentanoyl Chloride is synthesized by reacting valproic acid with an acid halide.  6. The process of claim 5, wherein the acid halide is selected from chlorosulfuric acid (CISO3H), sulfuryl chloride (SO2CI2), sulfuric acid (H2SO4), thionyl chloride (SOCI2), phosphorus trichloride, phosphorus oxychloride, or mixtures thereof and mixtures thereof in any proportion.  7. The process of claim 5, wherein the acid halide is thionyl chloride.  8. The process of claim 5, wherein the reaction of valproic acid with the acid halide occurs at a temperature ranging from about 25-30°C over a period of about 1 to 2 hours.  9. The process of claim 5, wherein after reacting valproic acid with the acid halide a resulting reaction mixture is purified to obtain 2-Propylpentanoyl Chloride by removing any traces of solvent and acid halide.  10. The process of claim 2, wherein the reaction of 2-Propylpentanoyl Chloride with Rflornithine HC1 in 5N Ag NaOH occurs at two different temperature ranging from about 5- 10° C for fist 12 hours and 25 to 30° C for next 36 hrs.  11. The process of claim 10, wherein pH of the reaction mass is maintained at 1 by adding 5N Aq. HC1.  12. The process of claim 11, wherein the reaction mass is charged with methanol and filtered to remove the methanol.  13. The process of claim 12, wherein the reaction mass is charged with acetone and hexane, then filtered and washed with acetone and hexane to obtain a final reaction mass.  14. The process of claim 13, the final reaction mass is dried for under vacuum at NMT 50-55°C to obtain the purified 2-Amino-2-(difluoromethyl)-5-(2-propylpentanamido) pentanoic acid hydrochloride.  15. The compound of claim 2, wherein the 2-Amino-2-(difluoromethyl)-5-(2- propylpentanamido) pentanoic acid hydrochloride is used for the treatment of cancer, trypanosomiasis and excessive hair growth. | treatment of cancer, trypanosomiasis, and excessive hair growth. |  |
| 43 | **RU0002761436** | 2021 |  | **Note:** Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters  **​[RU]**  ​Claims 1. A compound of Formula I,  2.    3. or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer or polymorph thereof,  4.  ​wherein X + is  5.    6.  ​for treating visual organ disorders or complications associated therewith.  7.  2. ​The compound of claim 1, which is selected from:  8.    9.    10.  3. ​The compound of claim 1, wherein said visual organ disorder is selected from the group consisting of macular degeneration, cataract, glaucoma, diabetic retinopathy, dry eye, eye neuritis, retinitis pigmentosa and presbyopia.  11.  4. ​A pharmaceutical composition for treating visual organ disorders or complications thereof, comprising an effective amount of at least one compound according to any one of claims 1, 2 and a pharmaceutically acceptable excipient.  12.  5. ​The pharmaceutical composition of claim 4, wherein said composition is formulated for oral, nasal, local, rectal, vaginal, aerosol or parenteral administration.  13.  6. ​The pharmaceutical composition of claim 4, wherein said composition is an ophthalmic formulation for topical use.  14.  7. ​The pharmaceutical composition of claim 4, wherein said composition is an ophthalmic formulation in the form of droplets.  15.  8. ​The method of synthesis of the compound of claim 1, wherein the method comprises treating the pilocarpine with lipoic acid.  16.  9. ​A method of treating visual organ disorders or complications thereof in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a compound of formula I,  17.    18.  ​or a pharmaceutically acceptable hydrate, solvate, crystal, co-crystal, enantiomer, stereoisomer, or polymorph thereof,  19.  ​wherein X + is  20.    21.  10. ​The method of claim 9, wherein said compound of formula I is selected from:  22.    23.    24.  11. ​The method of claim 9, wherein said administration comprises oral, nasal, topical, rectal, vaginal, aerosol or parenteral administration of said compound of Formula I  25.  12. ​The method of claim 9, wherein said compound of Formula I is administered to said subject in combination with a pharmaceutically acceptable excipient.  26.  13. ​The method of claim 9, wherein said compound of Formula I is administered topically in the form of eye drops, a tampon, an ointment, a gel, or a drug.  27.  14. ​The method of claim 9, wherein said compound of formula I is administered topically to at least one eye of said subject.  28.  15. ​The method of claim 9, wherein said therapeutically effective amount ranges from 0.001 mg to 1000 mg  29.  16. ​The method of claim 9, wherein said subject is a human.  30.  17. ​The method of claim 9, wherein said visual organ disorder is selected from the group consisting of macular degeneration, cataract, glaucoma, diabetic retinopathy, dry eye, eye neuritis, retinitis pigmentosa and presbyopia.  31.  18. ​Use of a compound according to any of claims 1, 2 for the manufacture of a medicament for the treatment of visual organ disorders or related complications. | treating visual organ disorders and/or complications thereof in a subject in need thereof by administering said compound, a method for synthesising said compound, as well as an application of said compound for producing a medicinal product for treating a visual organ disorder or complications associated therewith. |  |
| 44 | **WO2021240352** | 2021 |  | We claim:  1. A pharmaceutical composition for oral administration comprising pilocarpine R-(+)- lipoate or its polymorphs, enantiomers, isomers; and its pharmaceutically acceptable salts thereof.  2. The pharmaceutical composition of claim 1, wherein the pilocarpine R-(+)-lipoate is formulated in an amount of 1% to 70% w/w of the composition; and (ii) one or more excipients in an amount of 30 - 99 % w/w of the composition.  3. The pharmaceutical composition of claim 2, wherein the pilocarpine-R-(+)-lipoate is in the range of 0.1 mg to 100 mg.  4. The pharmaceutical composition of claim 2, wherein the one or more excipients are selected from a diluent, a lubricant, a disintegrant, a polymer, a flavoring agent, a binder, a sweeting agent, a glidant, an antioxidant, coating material, or mixtures thereof.  5. The pharmaceutical composition of claim 4, wherein the diluent is selected from lactose, spray dried lactose, lactose monohydrate, lactose hydrous, lactose anhydrous, starches, maize starches, or partially pregelatinized starches, sucrose, magnesium stearate, glucose, micro crystalline cellulose, Polyvinylpyrrolidone, mannitol, sorbitol, dibasic calcium phosphate dehydrate, calcium sulphate dehydrate, calcium carbonate, or mixtures thereof.  6. The pharmaceutical composition of claim 4, wherein the disintegrant is selected from crosslinked polymer such as polyvinylpyrrolidone (crospovidone) or crosslinked sodium carboxymethylcellulose (croscarmellose sodium), microcrystalline cellulose (MCC), alginates or modified starches, such as sodium starch glycolate, or mixtures thereof.  7. The pharmaceutical composition of claim 4, wherein the polymer is selected from carbomers, polycarbophil, pemulen polymers, starch, modified cellulose, crystalline cellulose, microcrystalline cellulose, carboxymethyl cellulose, sodium carboxymethylcellulose, an acrylic acid copolymer, methyl vinyl ether copolymer with maleic anhydride, hydro xypropyl methylcellulose, polyglycolic acid, or mixtures thereof.  8. The pharmaceutical composition of claim 4, wherein the flavoring agent is selected from clove oil, citric syrup, glycerin, rose oil, orange oil, menthol, cherry, or mixtures thereof.  9. The pharmaceutical composition of claim 4, wherein the binder, is selected from saccharides and their derivatives such as starches, cornstarch, cellulose, methyl cellulose and modified cellulose such as microcrystalline cellulose, cellulose ethers such as hydroxypropyl cellulose; sugar alcohols such as xylitol, sorbitol, or mannitol; protein: such as gelatin; synthetic polymers such as polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), or mixtures thereof.  10. The pharmaceutical composition of claim 4, wherein the sweeting agent is selected from sucrose, liquid glucose, glycerol, sorbitol, saccharin sodium, aspartame, or mixtures thereof.  11. The pharmaceutical composition of claim 4, wherein the glidant is selected from magnesium stearate, fumed silica (colloidal silicon dioxide), starch, talc, or mixtures thereof.  12. The pharmaceutical composition of claim 4, wherein the antioxidant is selected from butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite (SMB), propyl gallate (PG) cysteine (CYS), ascorbic acid, or mixtures thereof.  13. The pharmaceutical composition of claim 4, wherein the a coating material is selected from sugar, polymers, polysaccharides, moisture barrier coating material, cellulosic polymers, vinyl derivatives, hydroxypropyl cellulose, Hydroxyethyl cellulose microcrystalline cellulose, derivatives cellulose, alkylated cellulose, ethyl cellulose, propyl cellulose, hydroxylpropyl cellulose, sugar or a polysaccharide, hydroxypropyl methylcellulose, carboxymethylcellulose, maltodextrin, sucrose, modified starch, a salt of alginic acid, soluble gums, carrageenan, polymer comprises polyvinylpyrrolidone or polyvinylpolypyrrolidone, and Opadry film coating system.  14. The pharmaceutical composition of claim 4, wherein the coating of the composition is from sugar coatings, film coatings, gelatin coatings, enteric coatings, compression coatings, or immediate-release film coatings.  15. The pharmaceutical composition of claim 1, is a modified release composition wherein the modified release composition is formulated into mucoadhesive buccal tablet, lozenge, oral patch, oral film, buccal patch, oral spray, oral solution, oral gel, sub-lingual tablet, mucoadhesive patch or film or transdermal patch.  16. The pharmaceutical composition of claim 15, wherein the modified release is controlled by polymers and pharmaceutically acceptable excipients to deliver extended release, sustained release, or delayed release. | treatment of xerostomia, dry mouth and Sjogren's syndrome. |  |
| 45 | **IL287621** | 2021 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS |  |
| 46 | **WO2021234532** | 2021 |  | WE CLAIM:  1. A pharmaceutically acceptable composition comprising:  a. an active ingredient selected from 5-fluropyrimidine derivatives, their isomers, stereoisomers, diastereomers, enantiomers, prodrug and pharmaceutically acceptable salts thereof in an amount of 100- 3000 mg and comprising at least 60-85% by weight of the formulation;  b. one or more disintegrants or super disintegrants in an amount of 0.5 to 6 % by weight; c. one or more surfactants in an amount of 0.1 to 5% by weight;  d. one or more binders in an amount of 0.2 to 5%by weight; and  e. at least one lubricant in an amount of 0.3 to 3% by weight; wherein the pharmaceutically acceptable composition exhibits a friability of not more than 1 to 10%.  2. The pharmaceutically acceptable composition as claimed in claim 1 , wherein the composition comprises at least 500 mg 5 -fluropyrimidine ; derivative wherein 5-fluropyrimidine is derivative is (2R, 3R, 4R, 5R)-2-(5-Fluoro-4-octanamido2-oxopyrimidine- l(2H)-yl) -5- methyl- tetr ahydrofur an- 3 , 4-diyl- diacetate.  3. The phar maceut ic ally acceptable composition as claimed in claim 1, wherein the one or more disintegrants or super disintegrants is selected from polyvinylpyrrolidone, croscarmellose sodium, crospovidone, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, methyl cellulose, microcrystalline cellulose, powdered cellulose, lower alkyl- substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinized starch and sodium alginate.  4. The pharmaceutically acceptable composition as claimed in claim 1, wherein the one or more binders is selected from acacia, carbomer, carboxymethylcellulose, cellulose microcrystalline, copovidone, gelatin, glucose, lactose, guar gum, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acetate succinate, methyl cellulose, ethyl cellulose, polyethylene oxide, sodium alginate, povidone, starch, pregelatinized starch, ammonia methacrylate copolymer.  5. The pharmaceutically acceptable composition as claimed in claim 1, wherein the one or more surfactant is selected from sodium lauryl sulfate, ammonium lauryl sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, lauryldimethylamine oxide, Tween80, bile salts and thereof.  6. The pharmaceutically acceptable composition as claimed in claim 1, wherein the at least one lubricant is selected from calcium stearate, glyceryl behenate, magnesium stearate, mineral oil light, polyethylene glycol, castor oil, sodium stearyl fumarate, starch, stearic acid, talc, paraffin, hydrogenated vegetable oil, zinc stearate, sodium lauryl sulphate, sodium benzoate, PEG 400 and PEG 600.  7. The pharmaceutically acceptable composition as claimed in claim 1, wherein the composition is an immediate release, modified release composition such as sustained release, prolonged release, delayed release, pulsed release, controlled release, accelerated release, fast release, targeted release, gastric retention dosage release and thereof.  8. The pharmaceutically acceptable composition as claimed in claim 1 wherein the composition is administered for treating cancer. | treating cancers and its associated complications. |  |
| 47 | **IL287622** | 2021 |  | WE CLAIM:  1. A pharmaceutically acceptable composition comprising:  a. an active ingredient selected from 5-fluropyrimidine derivatives, their isomers, stereoisomers, diastereomers, enantiomers, prodrug and pharmaceutically acceptable salts thereof in an amount of 100- 3000 mg and comprising at least 60-85% by weight of the formulation;  b. one or more disintegrants or super disintegrants in an amount of 0.5 to 6 % by weight; c. one or more surfactants in an amount of 0.1 to 5% by weight;  d. one or more binders in an amount of 0.2 to 5%by weight; and  e. at least one lubricant in an amount of 0.3 to 3% by weight; wherein the pharmaceutically acceptable composition exhibits a friability of not more than 1 to 10%.  2. The pharmaceutically acceptable composition as claimed in claim 1 , wherein the composition comprises at least 500 mg 5 -fluropyrimidine ; derivative wherein 5-fluropyrimidine is derivative is (2R, 3R, 4R, 5R)-2-(5-Fluoro-4-octanamido2-oxopyrimidine- l(2H)-yl) -5- methyl- tetr ahydrofur an- 3 , 4-diyl- diacetate.  3. The phar maceut ic ally acceptable composition as claimed in claim 1, wherein the one or more disintegrants or super disintegrants is selected from polyvinylpyrrolidone, croscarmellose sodium, crospovidone, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, methyl cellulose, microcrystalline cellulose, powdered cellulose, lower alkyl- substituted hydroxypropyl cellulose, polacrilin potassium, starch, pregelatinized starch and sodium alginate.  4. The pharmaceutically acceptable composition as claimed in claim 1, wherein the one or more binders is selected from acacia, carbomer, carboxymethylcellulose, cellulose microcrystalline, copovidone, gelatin, glucose, lactose, guar gum, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, acetate succinate, methyl cellulose, ethyl cellulose, polyethylene oxide, sodium alginate, povidone, starch, pregelatinized starch, ammonia methacrylate copolymer.  5. The pharmaceutically acceptable composition as claimed in claim 1, wherein the one or more surfactant is selected from sodium lauryl sulfate, ammonium lauryl sulfate, dioctyl sodium sulfosuccinate, perfluorooctanesulfonate, lauryldimethylamine oxide, Tween80, bile salts and thereof.  6. The pharmaceutically acceptable composition as claimed in claim 1, wherein the at least one lubricant is selected from calcium stearate, glyceryl behenate, magnesium stearate, mineral oil light, polyethylene glycol, castor oil, sodium stearyl fumarate, starch, stearic acid, talc, paraffin, hydrogenated vegetable oil, zinc stearate, sodium lauryl sulphate, sodium benzoate, PEG 400 and PEG 600.  7. The pharmaceutically acceptable composition as claimed in claim 1, wherein the composition is an immediate release, modified release composition such as sustained release, prolonged release, delayed release, pulsed release, controlled release, accelerated release, fast release, targeted release, gastric retention dosage release and thereof.  8. The pharmaceutically acceptable composition as claimed in claim 1 wherein the composition is administered for treating cancer. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS |  |
| 48 | **WO2021229359** | 2021 |  | CLAIMS  We Claim:  1. A process for preparation of triazole salts comprises of:  a. the salt formation; by dissolving a triazole compound and a dilaurylglyceryl fumarate in a suitable polar solvents for formation of a triazole salt at a pre-determined temperate and time; and  b. isolation of the triazole salt using a non-polar cyclic or acyclic hydrocarbon solvent;  wherein the polar solvent for salt formation is selected from polar protic solvents or polar aprotic solvents; further the non-polar solvent for isolation of the triazole salt is selected from cyclic and acyclic hydrocarbons.  2. The process as claimed in claim 1, wherein the triazole compounds are posaconazole, voriconazole and itraconazole.  3. The process as claimed in claim 1 , wherein the polar protic solvents and polar aprotic solvents for salt formation comprises methanol, ethanol, isopropanol, water, acetonitrile, methyl tertiary butyl ether (MTBE), tetrahydrofuran, chlorinated solvent, dichloromethane, teracholoethane or chloroform preferably acetonitrile and dichloromethane.  4. The process as claimed in claim 1, wherein, the non-polar cyclic or acyclic hydrocarbon solvent for isolation comprises cyclohexane, hexane or heptane preferably hexane.  5. The process as claimed in o claim 1, wherein, the triazole salt are isolated in the form of amorphous salt, crystalline salt or a combination.  6. The process as claimed in claim 1 claim 1, wherein the triazole salts are dilauryl glyceryl fumarate of posaconazole, dilauryl glyceryl fumarate of voriconazole and dilauryl glyceryl fumarate of itraconazole.  7. The process according to claim 1 or 6, wherein the preparation of dilauryl glyceryl fumarate of posaconazole comprises of:  a. dissolving posaconazole and dilaurylglyceryl fumarate in the acetonitrile and heating the reaction mixture to a temperature about 50-55°C for 180 minutes with continuous stirring to obtain a clear solutions;  b. acetonitrile is distilled off from the reaction mixture at temperature not exceeding 40°C to obtain a white solid having the dilauryl glyceryl fumarate of posaconazole; and  c. dilauryl glyceryl fumarate of posaconazole is isolated from the white solid by washing and filtering the solid in hexane to yield above 97.3 % dilauryl glyceryl fumarate of posaconazole as white solid.  8. The process as claimed in claim 1 or 6, wherein the preparation of dilauryl glyceryl fumarate of voriconazole comprises of:  a. dissolving voriconazole and dilaurylglyceryl fumarate in the acetonitrile and heating the reaction mixture to a temperature about 50-55°C for 180 minutes with continuous stirring to obtain a clear solutions;  b. acetonitrile is distilled off from the reaction mixture at temperature not exceeding 40°C to obtain a solid mixture having the dilauryl glyceryl fumarate of voriconazole; and  c. dilauryl glyceryl fumarate of voriconazole is isolated from the solid mixture by washing, filtering drying the solid mixture in hexane to yield above 98.8 % dilauryl glyceryl fumarate of voriconazole as off white solid.  9. The process as claimed in claim 1 or 6, wherein the preparation of dilauryl glyceryl fumarate of itraconazole comprises of:  a. dissolving itraconazole and dilaurylglyceryl fumarate in the dichloromethane and heating the reaction mixture to a temperature about 35-38°C for 120 minutes with continuous stirring, this mixture is subjected to carbon treatment for 60 minute and the mixture is filtered through a hyflo bed and washed with dichloromethane; b. dichloromethane is distilled off from the reaction mixture at temperature not exceeding 40°C to obtain a solid mixture having the dilauryl glyceryl fumarate of itraconazole; and  c. dilauryl glyceryl fumarate of itraconazole is isolated from the solid mixture by washing, filtering drying the solid mixture in hexane to yield above 98.7 % dilauryl glyceryl fumarate of itraconazole as light yellow solid.  10. The triazole salts prepared by the process according to claims 7 to 9, are processed using a chemical process or physical manipulation to obtain a particle size ranging from 0.001 micron to 100 micron through. | It further discloses a method of producing fine particulate size of the dilauryl glyceryl fumarate salt of triazole preferably in the size ranging from 0.001micron to 100micron. It also discloses a method of preparing a desired pharmaceutical preparation. |  |
| 49 | **IN202148045338** | 2021 |  | 1. A compound of Formula IV: Formula IVand pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;wherein,RH is ;wherein, within the provisoR1, R2, R3 independently represents , , or . 2. A compound of Formula V: Formula Vand pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;Wherein,RH is ;wherein, within the provisoR1, R2, R3 independently represents , , or . 3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 5. A compound of claim 1, comprising of formula IV: . , | treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 50 | **JP2021152048** | 2021 |  |  | provide a compound to treat, prevent a clinical condition, such as chronic pain, and/or improve their effect, pharmaceutical compositions containing the compound, and a method for using the same. |  |
| 51 | **EP3883544** | 2021 |  |  | pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders. |  |
| 52 | **US20210277050** | 2021 |  | and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof,  wherein  R 1independently represents Null,              18. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.  19. The pharmaceutical composition of claim 18, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.  20. The pharmaceutical composition of claim 19, wherein said pharmaceutical administration is formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye or oGVHD.  21. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable carrier.  22. The pharmaceutical composition of claim 21, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.  23. The pharmaceutical composition of claim 22, wherein said pharmaceutical administration is formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye or oGVHD.  24.- 68. (canceled)  69. A compound of the structure selected from a group consisting of      70. A pharmaceutical composition comprising a compound of claim 69, and a pharmaceutically acceptable carrier.  71. The pharmaceutical composition of claim 70, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, ocular administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.  72. The pharmaceutical composition of claim 71, wherein said pharmaceutical administration is formulated for the treatment of glaucoma, presbyopia, IOP, cataract, dry eye or oGVHD. | treatment of eye diseases may be formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 53 | **US20210269412** | 2021 |  | Claims  1. (canceled)  2. A compound of formula II    and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof,  wherein  X + independently represents               |  | | --- | | wherein  n=0-18. | | **3**.- **5**. (canceled) | | **6**. A compound of formula VI      caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, 1 auric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidie acid, arachidonic acid, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxychoiecaiciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobaiamin, choline, or dehydroascorbic acid, 1-docosanol.  nd pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof  wherein  R 1independently represents null, |   caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, or dehydroascorbic acid, 1-docosanol  9. (canceled)  10. (canceled)  11. (canceled)  12. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable carrier.  13. The pharmaceutical composition of claim 12, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.  14. The pharmaceutical composition of claim 13, wherein said composition is formulated for the treatment of inflammatory skin diseases or cancer.  15.- 23. (canceled)  24. A pharmaceutical composition comprising a compound of claim 6, and a pharmaceutically acceptable carrier.  25. The pharmaceutical composition of claim 24, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.  26. The pharmaceutical composition of claim 25, wherein said composition is formulated for the treatment of inflammatory skin diseases or cancer.  27. (canceled)  28. (canceled)  29. (canceled)  30. A pharmaceutical composition comprising a compound of claim 8, and a pharmaceutically acceptable carrier.  31. The pharmaceutical composition of claim 30, wherein said pharmaceutical composition is formulated for oral administration, parenteral administration, topical administration, injection, subdermal administration, transdermal administration, oral solution, nasal spray, oral spray, rectal administration, buccal administration or transmucosal administration.  32. The pharmaceutical composition of claim 31, wherein said composition is formulated for the treatment of inflammatory skin diseases or cancer.  33. (canceled)  34. A compound of claim 6, wherein the structure is     |  | | --- | | **35**. A pharmaceutical composition comprising a compound of [**claim 34**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US335022812&_cid=P12-L9KZ4D-43227-6#CLM-00034), and a pharmaceutically acceptable carrier. | | **36**. A compound of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US335022812&_cid=P12-L9KZ4D-43227-6#CLM-00008), wherein the structure is selected from a group consisting of |     37. A pharmaceutical composition comprising a compound of claim 36, and a pharmaceutically acceptable carrier.  38. A compound of claim 2, wherein the structure is    **39**. A pharmaceutical composition comprising a compound of [**claim 38**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US335022812&_cid=P12-L9KZ4D-43227-6#CLM-00038), and a pharmaceutically acceptable carrier. | treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers. |  |
| 54 | **BR112021009700** | 2021 |  |  | treatment of ocular disorders and skin diseases, and can be formulated for topical eye, topical paste, ocular solution, administration of a medication device, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, ointment, gels, lotions​. |  |
| 55 | **US20210244687** | 2021 |  | |  | | --- | | **1**. (canceled) | | **2**. (canceled) | | **3**. A compound of Formula III: |     and a pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof, wherein  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone, menaquinones, menadione, menadiol, thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein within the proviso R 1, R 2, R 3independently represents     |  | | --- | | **4**. (canceled) | | **5**. A compound of Formula V:    and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof, herein;  RH independently represents  phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin A, retinol, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone, menaquinones, menadione, menadiol, thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or | | |  | | --- | | **6**.- **16**. (canceled) | | **17**. A pharmaceutical composition comprising a compound of [**claim 3**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00003) and a pharmaceutically acceptable carrier. | | **18**. (canceled) | | **19**. A pharmaceutical composition comprising a compound of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00005) and a pharmaceutically acceptable carrier. | | **20**.- **30**. (canceled) | | **31**. The pharmaceutical composition of [**claim 17**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00017), wherein said pharmaceutical composition is formulated to treat a patient with an effective amount of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **32**. (canceled) | | **33**. The pharmaceutical composition of [**claim 19**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00019), wherein said pharmaceutical composition is formulated to treat a patient with an effective amount of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **34**.- **44**. (canceled) | | **45**. The pharmaceutical compositions of [**claim 31**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00031), wherein said pharmaceutical composition is formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | **46**. (canceled) | | **47**. The pharmaceutical compositions of [**claim 33**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00033), wherein said pharmaceutical composition is formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | **48**.- **57**. (canceled) | | **58**. A compound of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00005), comprising of formula V: |      |  | | --- | | **59**. (canceled) | | **60**. A pharmaceutical composition comprising a compound of [**claim 58**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00058) and a pharmaceutically acceptable carrier. | | **61**. The pharmaceutical composition of [**claim 60**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00060), wherein said pharmaceutical composition is formulated to treat a patient with an effective amount of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **62**. The pharmaceutical compositions of [**claim 61**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US333350066&_cid=P12-L9KZ4D-43227-6#CLM-00061), wherein said pharmaceutical composition is formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 56 | **EP3860592** | 2021 |  |  | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases and eye diseases. |  |
| 57 | **IN202148033681** | 2021 |  | 1. A compound of Formula V: Formula Vand pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;wherein,RH is ;wherein, each R1, R2 and R3 independently represents , , , , , , , , , , , , , , , ,or . 2. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 3. A compound of claim 1, wherein the compound has the chemical structure of: . , | TREATMENT OF FUNGAL INFECTIONSThe invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 58 | **IN202148033683** | 2021 |  | 1. A compound of Formula II: Formula IIand pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;wherein,RH is ; ;wherein, each R1, R2 and R3 independently represents , , , , , , , , , , , , , , , ,or . 2. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier. 3. A compound of claim 1, wherein the compound has the chemical structure of: , . , | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 59 | **IN202148033682** | 2021 |  | 1. A compound of formula IX: Formula IXand pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;wherein,RH is ;wherein, each R1, R2 and R3 independently represents , , , , , , , , , , , , , , , ,or . 2. A pharmaceutical composition comprising a compound of claim 26 and a pharmaceutically acceptable carrier. 3. A compound of claim 1, wherein the compound has the chemical structure of: . , | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 60 | **IN202148033680** | 2021 |  | 1. compound of Formula III: Formula IIIand pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;wherein,RH is ;wherein, each R1, R2 and R3 independently represents , , , , , , , , , , , , , , or . 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 3. A compound of claim 1, wherein the compound has the chemical structure of: . , | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 61 | **NZ777654** | 2021 |  |  | The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a selective alpha-adrenergic receptor agonist or an anticholinergic agentor a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the selective alpha-adrenergic receptor agonist or anticholinergic agent is selected from the group consisting of pilocarpine, brimonidine and oxymetazoline, or a pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders. |  |
| 62 | **SG11202106716R** |  |  |  | The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a selective alpha-adrenergic receptor agonist or an anticholinergic agentor a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the selective alpha-adrenergic receptor agonist or anticholinergic agent is selected from the group consisting of pilocarpine, brimonidine and oxymetazoline, or a pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders. |  |
| 63 | **EP3852722** | 2021 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease as well as scleroderma, restless leg syndrome, hypertension and gestational hypertension. |  |
| 64 | **AU2021203748** | 2021 |  | 1. A compound of formula I:    and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R 1, R3represents CD 3 , CD2, H, D, O, OD, CD3CO, NULL,              Within the proviso, Wherein  n represents 0 to 12;  R 5 and R6 independently represents      and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R 1, R3represents CD 3 , CD2, H, D, O, OD, CD3CO, NULL,              Within the proviso, Wherein  n represents 0 to 12;  R 5 and R6 independently represents      and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R 1, R3, R 5 represents CD3 , CD2, H, D, 0, OD, CD3CO, NULL,              Within the proviso, Wherein  n represents 0 to 12;  R 6 independently represents NULL,        and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R 1, R3, R5, R7represents CD 3 , CD 2, H, D, 0, OD, CD3CO, NULL,            Within the proviso, Wherein  n represents 0 to 12;  R 5 and R6 independently represents      and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R1, R3, R 5represents CD3,CD 2, H, D, 0, OD, CD3CO, NULL,                Within the proviso, Wherein  n represents 0 to 12;  R 5 and R6 independently represents      and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R 1, R3, R 5represents CD3,CD 2, H, D, 0, OD, CD3CO, NULL,                  Within the proviso,  Wherein  n represents 0 to 12;  R 5 and R6 independently represents        and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R  1, R3represents   CD  3, CD2,  H,  D,  O,  OD,  CD3CO,  NULL,          Within the proviso,  Wherein  n represents 0 to 12;  R5 and R6 independently represents      and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R 1 represents CD3 , CD2, H, D, 0, OD, CD3CO, NULL              Within the proviso,  Wherein  n represents 0 to 12;  R5 and R6 independently represents      9.        A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  10.      A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.  11.      A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.  12.      A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.  13.      A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.  14.      A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.  15.      A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.  16.      A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier.  17.      The pharmaceutical composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  18.      The pharmaceutical composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  19.      The pharmaceutical composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  20.      The pharmaceutical composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  21.      The pharmaceutical composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  22.      The pharmaceutical composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  23.      The pharmaceutical composition of claim 15, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  24.      The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  25.      Compounds and compositions of claim 17 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  26.      Compounds and compositions of claim 18 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  27.      Compounds and compositions of claim 19 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  28.      Compounds and compositions of claim 20 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  29.      Compounds and compositions of claim 21 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  30.      Compounds and compositions of claim 22 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  31.      Compounds and compositions of claim 23 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases.  32.      Compounds and compositions of claim 24 are formulated for the treatment of colorectal cancer, breast cancer (metastatic or as monotherapy/combotherapy), gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers (especially head and neck cancers), actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis and oral infectious diseases. | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 65 | **IL282898** | 2021 |  |  | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES AND EYE DISEASES |  |
| 67 | **SG10202104160T** | 2022 |  | CLAIMS  1. A compound of Formula I:    Formula I  and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R', R3, R5 each independently represents OD, OCH3, OCOCH3, NULL,                    n is independently 1, 2, 3, 4 or 5;  a is independently 2,3 or 7;  each b is independently 3, 5 or 6;  e is independently 1, 2 or 6;  c and d are each independently H, D, -OH, -OD, C1-C6-alkyl, -NH2 or -COCH3.  2. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  3. The pharmaceutical composition of claim 2, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  4. Compounds and compositions of claim 3 are formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation.  5. A method of treating at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease comprising:  administering the compound of Formula I to patient suffering from at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease | The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal , lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administra tion, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications. |  |
| 67 | **SG10202105113S** | 2021 |  |  | treatment of oral in fectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal , lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administra tion, syrup, or injection. |  |
| 68 | **SG10202105118** | 2021 |  |  | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such com positions may be used to treatment of fungal infections. |  |
| 69 | **SG11202104410S** | 2021 |  |  | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases and eye diseases. |  |
| 70 | **US20210188817** | 2021 |  | **1**. A compound of Formula I:    and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  RH independently represents    caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, aspartic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), cinnamic acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, galactaric acid, glucoheptonic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, malic acid, malonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, proprionic acid, pyroglutamic acid, sebacic acid, thiocyanic acid, undecylenic acid, omega 3 fatty acids, alpha linoleic acid, alpha linolenic acid, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, phospholipids, phosphatidylcholine, elaidic acid, linoleic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, dehydroascorbic acid or 1-docosanol.  2.- 6. (canceled)  7. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  8. The pharmaceutical composition of claim 7, wherein said pharmaceutical composition is for oral administration, oral solution, dermal, dermal ointment, cream, lotions, suspension, gels, ocular, injection, topical eye drop, spray, subdermal administration, or transdermal administration.  9. The pharmaceutical compositions of claim 8, are formulated for the treatment of eye disorders and skin diseases.  10.- 24. (canceled)  25. A compound selected from a group consisting of:      26. A pharmaceutical composition comprising one or more compounds of claim 25 and a pharmaceutically acceptable carrier.  27. The pharmaceutical composition of claim 26, wherein said pharmaceutical composition is for oral administration, oral solution, dermal, dermal ointment, cream, lotions, suspension, gels, ocular, injection, topical eye drop, spray, subdermal administration, or transdermal administration.  28. The pharmaceutical compositions of claim 27, are formulated for the treatment of eye disorders and skin diseases. | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 71 | **IN202147021049** | 2021 |  |  | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases and eye diseases. |  |
| 72 | **US20210171564** | 2021 |  | Claims   1. A compound of Formula I:     and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  wherein  R 1, R 3, R 5 independently represents NULL,      R 2, R 4independently represent NULL, hydrogen,      within the proviso,  wherein  n represents 0 to 12;  R 7and R 8independently represents    with the proviso that when R 2and R 4is hydrogen then R 6is not      and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof,  wherein  R 1, R 3, R 5independently represents NULL,      R 2, R 4independently represent NULL, hydrogen,          with the proviso that when R 2and R 4is hydrogen then R 6is not     |  | | --- | | **3**. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00001) and a pharmaceutically acceptable carrier. | | **4**. The pharmaceutical composition of [**claim 3**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00003), wherein said pharmaceutical composition is for oral administration, systemic administration, sustained release, parenteral administration, injection, dermal administration, drug-device, topical administration, subdermal administration, solution, syrup, or transdermal administration. | | **5**. The pharmaceutical compositions of [**claim 4**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00004), wherein said pharmaceutical composition is formulated for the treatment of cancer. | | **6**. A pharmaceutical composition comprising a compound of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00002) and a pharmaceutically acceptable carrier. | | **7**. The pharmaceutical composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00006), wherein said pharmaceutical composition is for oral administration, systemic administration, sustained release, parenteral administration, injection, dermal administration, drug-device, topical administration, subdermal administration, solution, syrup, or transdermal administration. | | **8**. The pharmaceutical compositions of [**claim 7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00007), wherein said pharmaceutical composition is formulated for the treatment of cancer. | | **9**. A compound selected from the group consisting of |      |  | | --- | | **10**. A pharmaceutical composition comprising a compound of [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00009) and a pharmaceutically acceptable carrier. | | **11**. The pharmaceutical composition of [**claim 10**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00010), wherein said pharmaceutical composition is for oral administration, systemic administration, sustained release, parenteral administration, injection, dermal administration, drug-device, topical administration, subdermal administration, solution, syrup, or transdermal administration. | | **12**. The pharmaceutical composition of [**claim 11**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US326379203&_cid=P12-L9KZ4D-43227-8#CLM-00011), wherein said pharmaceutical composition is formulated for the treatment of cancer. | | The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications. |  |
| 73 | **NZ775824** | 2021 |  |  | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases and eye diseases. |  |
| 74 | **SG10202103034U** | 2021 |  | 1. A compound of Formula I    Formula I  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents   ,1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  2. A compound of Formula II:    Formula II  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents   ,1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-  hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, gl ycerophosphoric acid, glycolic acid, hippuri c acid, h ydrobromi c acid, i sobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.    and pharmaceutically acceptable hydrates, solvates, prodrugs, en anti omers, and stereoisomers thereof;  Wherein,  RH independently represents   ,1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2- hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.    Formula  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents   ,1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2- hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, gl ycerophosphoric acid, glycolic acid, hippuri c acid, hydrobromi c acid, i sobutyric acid, lactic acid, 1 actobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- l ,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  5. A compound of Formula V:    Formula V  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents   ,I -hydroxy-2-naphtlioic acid, 2,2-dichloroacetic acid, 2- hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid.  6. A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  7. A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.  8. A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.  9. A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.  10. A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.  11. The pharmaceutical composition of claim 6, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  12. The pharmaceutical composition of claim 7, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  13. The pharmaceutical composition of claim 8, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  14. The pharmaceutical composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  15. The pharmaceutical composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  16. Compounds and compositions of claim 11 are formulated for the treatment of xerostomia, dry mouth and dry mouth in Sjogren's syndrome.  17. Compounds and compositions of claim 12 are formulated for the treatment of xerostomia, dry mouth and dry mouth in Sjogren's syndrome.  18. Compounds and compositions of claim 13 are formulated for the treatment of xerostomia, dry mouth and dry mouth in Sjogren's syndrome.  19. Compounds and compositions of claim 14 are formulated for the treatment of xerostomia, dry mouth and dry mouth in Sjogren's syndrome.  20. Compounds and compositions of claim 15 are formulated for the treatment of xerostomia, dry mouth and dry mouth in Sjogren's syndrome. | treatment of xerostom ia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spra y, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry m outh or oral dry mouth mediated infectious diseases. |  |
| 75 | **EP3823603** | 2021 |  |  | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 76 | **BR112021003452** |  |  |  | treating ocular disorders and skin diseases, and can be formulated for topical eye, topical paste, ocular solution​delivery of a device drug, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, by spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal, parenteral, syrup or injection layer tablet.​these compositions can be used for the treatment of skin diseases, such as acne, rosacea, and ocular disorders such as ocular redness, glaucoma, presbyopia, pio, cataract, dry eye and ogvhd. |  |
| 77 | **EP3817732** | 2021 |  |  | The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications. |  |
| 78 | **EP3813794** | 2021 |  |  | formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD. |  |
| 79 | **BR112021001652** | 2021 |  |  | These conjugates can be formulated as pharmaceutical compositions. The pharmaceutical compositions can be formulated for oral, intravenous, solution, syrup, sachet, transdermal administration, or injection purposes.​these compositions can be used for the treatment of cancer or its associated complications. |  |
| 80 | **SG11202102369V** | 2021 |  |  | treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. |  |
| 81 | **IN202147016619** | 2021 |  |  | treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease as well as scleroderma, restless leg syndrome, hypertension and gestational hypertension. |  |
| 82 | **SG11202100985Q** | 2021 |  |  | PHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS AND SKIN DISEASES |  |
| 83 | **SG10202101247Q** | 2021 |  |  | These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administra tion, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications. |  |
| 84 | **NZ774005** | 2021 |  |  | treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, subcutaneous, depot, intramuscular, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease as well as scleroderma, restless leg syndrome, hypertension and gestational hypertension. |  |
| 85 | **NZ774213** | 2021 |  |  | treatment of skin diseases such as acne, rosacea and eye disorders such as ocular redness, glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD. |  |
| 86 | **IL280588** | 2021 |  |  | TREATMENT OF EYE DISORDERS AND SKIN DISEASES |  |
| 87 | **IL280587** | 2021 |  |  | FLUROCYTIDINE DERIVATIVES AND ITS COMPOSITION FOR THE TREATMENT OF CANCER |  |
| 88 | **EP3793522** | 2021 |  |  | treatment of inflammatory skin diseases and cancer may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers. |  |
| 89 | **US20210078983** | 2021 |  | 1. A compound of formula I     and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; wherein  R 1, R 3represents CD 3, CD 2, H, D, O, OD, CD 3CO, NULL,      R 2, R 4independently represents    within the proviso, wherein  n represents 0 to 12;  R 5and R 6independently represents     |  | | --- | | **2**. (canceled) | | **3**. A compound of formula III: |     and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; wherein  R 1, R 3, R 5represents CD 3, CD 2, H, D, O, OD, CD 3CO, NULL,      R 2, R 4independently represents    within the proviso, wherein  n represents 0 to 12;  R 6independently represents NULL,     |  | | --- | | **4**.- **7**. (canceled) | | **8**. A compound of formula VIII: |     and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; wherein  R 1represents CD 3, CD 2, H, D, O, OD, CD 3CO, NULL,        within the proviso,  wherein  n represents 0 to 12;  R 5and R 6independently represent:     |  | | --- | | **9**. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00001) and a pharmaceutically acceptable carrier. | | **10**. (canceled) | | **11**. A pharmaceutical composition comprising a compound of [**claim 3**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00003) and a pharmaceutically acceptable carrier. | | **12**.- **15**. (canceled) | | **16**. A pharmaceutical composition comprising a compound of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00008) and a pharmaceutically acceptable carrier. | | **17**. The pharmaceutical composition of [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00009), wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient in need by administering an effective amount of said pharmaceutical composition to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **18**. (canceled) | | **19**. The pharmaceutical composition of [**claim 11**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00011), wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient in need by administration an effective amount of said pharmaceutical composition to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **20**.- **23**. (canceled) | | **21**. The pharmaceutical composition of [**claim 16**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00016), wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient in need by administering an effective amount of said pharmaceutical composition to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **24**. The pharmaceutical composition of [**claim 17**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00017), wherein said pharmaceutical composition is formulated for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, head and neck cancers, actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis or oral infectious diseases. | | **25**. (canceled) | | **26**. The pharmaceutical composition of [**claim 19**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00019), wherein said pharmaceutical composition is formulated for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, head and neck cancers, actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis or oral infectious diseases. | | **27**.- **31**. (canceled) | | **32**. The pharmaceutical composition of [**claim 24**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US320327950&_cid=P12-L9KZ4D-43227-9#CLM-00024), wherein said pharmaceutical composition is formulated for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, head and neck cancers, actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis or infectious diseases. | | treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases. |  |
| 90 | **IL280262** | 2021 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |  |
| 91 | **US20210053950** | 2021 |  | A compound of formula X    or a pharmaceutically acceptable hydrate, solvate, enantiomers or a stereoisomer thereof,  wherein  RH is selected from 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, ascorbic acid, aspartic acid, camphoric acid, camphor-10-sulfonic acid, carbonic acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hydrobromic acid, lactic acid, lactobionic acid, lauric acid, mandelic acid, nicotinic acid, oleic acid, oxalic acid, pamoic acid, pyroglutamic acid, sebacic acid, thiocyanic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, alpha lipoic acid, R-lipoic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid and arachidonic acid    wherein R 1, R 2and R 3independently represents         |  | | --- | | 2. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00001) and a pharmaceutically acceptable carrier. | | 3. The pharmaceutical composition of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00002), wherein said pharmaceutical composition is formulated with an effective amount of compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00001) for oral administration, transmucosal administration, parenteral administration, intravenous administration, subdermal administration, rectal administration, buccal administration or transdermal administration. | | 4. A method of using of the pharmaceutical composition of [**claim 3**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00003) for treatment of fungal infections, candidiasis and oral infectious diseases, wherein the treatment is therapeutic treatment. | | 5. A compound selected from a group consisting of: |        |  | | --- | | 6. A pharmaceutical composition comprising a compound of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00005) and a pharmaceutically acceptable carrier. | | 7. The pharmaceutical composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00006), wherein said pharmaceutical composition is formulated with an effective amount of compound of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00005) for oral administration, transmucosal administration, parenteral administration, intravenous administration, subdermal administration, rectal administration, buccal administration or transdermal administration. | | 8. A method of using of the pharmaceutical composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US318501027&_cid=P12-L9KZ4D-43227-10#CLM-00006) for treatment of fungal infections, candidiasis and oral infectious diseases, wherein the treatment is therapeutic treatment. | | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 92 | **SG11202100411T** | 2021 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |  |
| 93 | **IN202147006223** | 2021 |  |  | formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications. |  |
| 94 | **IN202147006224** | 2021 |  |  | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of skin diseases such as acne, rosacea and eye disorders such as ocular redness, glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD. |  |
| 95 | **US20210032194** | 2021 |  | 1. A compound of Formula     wherein  RH is caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1, 25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or     |  | | --- | | or pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof. | | **3**. A compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00001), wherein the ketamine moiety in the compound of formula I is selected from an R enantiomer, an S enantiomer, or a racemic mixture comprising equal portions of R and S enantiomers of the ketamine. | | **4**. A compound of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00002), wherein the ketamine moiety in the compound of formula II is an S-enantiomer of the ketamine. | | **5**. A compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00001), wherein the compound is selected from a group consisting of |   and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof.  6. A compound of claim 2, wherein the compound is selected from a group consisting of    and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof.  7. A compound of Formula III         |  | | --- | | or pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof. | | **8**. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00001) as an active ingredient in a therapeutically effective amount; and a pharmaceutically acceptable excipient and/or pharmaceutically acceptable carrier. | | **9**. The pharmaceutical composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00008), wherein the pharmaceutically acceptable excipient is selected from the group comprising of a stabilizer, an inert carrier, a vehicle, a diluent, a surfactant, a filler, a humectant, an adsorbent, an antiadherent, a binder, a lubricant, a glidant, a super disintegrant, a disintegrant, a preservative, an antioxidant, a solution retarding agent, an absorption accelerator, a wetting agent, an absorbent, a coloring agent, a flavoring agent, a sorbent, a coating agent, a sweetener, a buffering agent, a propellant, and mixtures thereof. | | **10**. The pharmaceutical composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00008), wherein the pharmaceutical composition is formulated as an oral dosage form, systemic dosage form, topical dosage form, spray, parenteral dosage form, subdermal dosage form, or transdermal dosage form. | | **11**. The pharmaceutical composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00008), wherein the pharmaceutical composition is formulated in a unit dosage form selected from the group consisting of tablet, sublingual tablet, mucoadhesive tablet, multilayer tablet, capsule, capsules containing tablet, controlled-release form, sustained-release form, suppository, tampons, pessaries, pill, lozenge, powder, beads, granule, nanoparticles, beads or granules in solid or liquid forms, oral spray, nasal spray, mucoadhesive spray, intra nasal spray, foam, nasal inhaler, liquid solution, syrups, elixirs, emulsions, microemulsions, subdermal autoinjector, intramuscular autoinjector, injection, stereotactic injection, liquid suspension, intravenous suspension, sterile parenteral solution, sterile parenteral suspension, sterile non-parenteral solution, sterile non-parenteral suspension, topical ointment, topical paste, topical cream, topical lotion, topical gel, and transdermal patch. | | **12**. A method of the treatment, prevention or amelioration of a neurological diseases or an associated complication comprising administering to a subject the compound as claimed in any one of the [**claims 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00001) to [**7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00007) as an active ingredient in a therapeutically effective amount, or the pharmaceutical composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00008). | | **13**. The method as claimed in [**claim 12**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00012), wherein the associated complication is selected from the group consisting of depression, treatment resistant depression, chronic pain and neurological diseases. | | **14**. A kit comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00001) as an active ingredient in a therapeutically effective amount, and an instruction or use in the treatment of neurological diseases and associated complications. | | **15**. A kit comprising a pharmaceutical composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US317294999&_cid=P12-L9KZ4D-43227-10#CLM-00008), and an instruction for use in the treatment of neurological diseases and associated complications. | |  |  |
| 96 | **AU2020321680** | 2021 |  | 1. A compound of formula I    or a pharmaceutical acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2 oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-O-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,        wherein, within the proviso  each R6 , R7 and Rgindependently represents          within the proviso;  n =O0to 80.  R1 represents null,        and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2 oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-O-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, , myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,                    and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2 oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-O-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, , myristic acid, myristoleic acid, palmitoleic acid,, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,                and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2 oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-O-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene 1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, , myristic acid, myristoleic acid, palmitoleic acid,, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid, | for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermaladministration, spray, injection or other known formulation in the art. |  |
| 97 | **CA3149128** | 2021 |  | We Claim:  1. A compound of formula I  Ri-0 N p / RH  or a pharmaceutical acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  Br  OH  Br  H H2  N N N H H H OH 0 N N 2 /444. .'",...T./ N 1 1 I-\_\_\_\_>  OH  N HO N 0 , ,  N 0H ).\_\_\_\_\_ 0 1 NH  OH  OH  OH\*\_--OH  Hf\'10H o  H N+ 0 1 OH  OH µ  H2N .=sssµµµµOH  HOOH  0 OH 1:\_--N OH  N N'''. NH  1 OH  L--S  NH2 OH  N OH  1 L OH  N NH3 S  OH  CI  NH2  H H  H2N W N OH N NH2  F F CI 0 CI 0  NH2  H H2  J. N N  H3 N OH D+ H N+1 N H2  F F CI  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  NH2 0  NH  H2N N OH ......,........,, ,.....,....,õ..,...,,,.,,OH  H2N N  NH  N' H3 0 1 + OH  H2N N H2 OH H3N N  N1+  HO 1 0  Fl CI  H H / N  N N  HO  OE / . \--.------\_\_\_)  HO  OE  H3 cl  + ,  0 OH  W , '  HO N  HNI..j  N OH  OH  \_NI0  H3N 0 OH+  H2 OH , ,  HS  OH  OH  H2N\*%'....%''''''''''-'%%....%%'-..'-.--'-..%%\*\*I-Tj12......'.....'''''''....Y..........H2 ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  HS 0 ---R7  OH  NH3 or = wherein, within the proviso each R6, R7 and R8 independently represents  OH 0 0 0 0 0 OH  0 0  HO yrr  HOC -Prrr 5W/SOH 0 OH  HO  OH 0 OH 0  srss\/\,5 (jr, 0 OH 0  NOH OH (5H 0  NIE)  5H 0  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  HO.:...>"r  RH2  µ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ . \_\_\_\_\_\_\_\_\_ . \SI 1 \e/ 14 '''''1- \ "<"  .".. \ OH , .  cSS3 SC.41/4..-12 1%.  C3, --e- -se' .$)  \\õ,,,,,/,µ,,,\_ õ.".\.õ., .""'",, e"¨\\õµ,....,,\,,,,,..,.N.,,,,,,,"=..õ,õ." '\,..,/,5  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  0 HO ss55  0 OH  HO....................................õ, c5  CS' HOWOH HOWOH 0 OH  o o o o )222. o 07 o ,................õõõ-,,,,,..............v  HOWOH OWOH  O ../VVV' OH 0 OH 0 OH  HOW/ sS5 µZ2z,WOH  OH n OH ,  O c)o  OW,S HCIss5 c555OH  OH 0 OH 0 OH  'atW OH  O OH o a  sSS5,5 o o o OH CCSSS Or OH ;  within the proviso; n = 0 to 80.  Itl represents null,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  (õ) <  0 0 sSS  NH2 ,  Ao N  PrPr or  R2 represents  (?77HOssjs  H2 NN,s-r so o  cSj n = 0 - 40 (z.  (772.  rPrr  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  \_ \_ \_  NH2 -.....,,,.  N OH  LI/ , , ,  S/  ();%,  Nr  L'LLt, W  1 /01  SSLO  H2N 0  N OH  OH H2,  /7-\\  F' \ \ 1 ).---O \ / \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ /  X'= ----1  ( 0 02 .  H ,  OH 0  N+ = (.5,S. 0 or r =  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  2. A compound of formula II  Ri ¨0 N p / RH  H2N ....j  Formula II and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-1 0-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acidõ myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  Br  OH  Br  H H2  N N N H H H OH 0 N N 2 /444. .'",...T./ N 1 1 I-\_\_\_\_>  OH  N HO N 0 , ,  N 0H ).\_\_\_\_\_ 0 1 NH  OH  OH  OH\*\_--OH  Hf\'10H o  H N+ 0 1 OH  OH µ  H2N .=sssµµµµOH  HOOH  0 OH 1:\_--N OH  N N'''. NH  1 OH  L--S  NH2 OH  N OH  1 L OH  N NH3 S  OH  CI  NH2  H H  H2N W N OH N NH2  F F CI 0 CI 0  NH2  H H2  J. N N  H3 N OH D+ H N+1 N H2  F F CI  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  NH2 0  NH  H2N N ......,........,,N,.....,..,...,...\_õ,..,OH ..12 , OH  H2N  NH  N'H3 0 1 + OH  H2N N OH H3N  H2 N  N1+  HO 0  N H CI  N N 00H  HO HO  HN ------>  H3 W t) '0-  HO HN-----..> N  N OH  OH  -S,  0 OH 0  H N+  H2 OH  H2N HS  OH OH %%...'''.....\*--12 L'..%%.\* , .............:11 ,  HS t \_\_ 0 -P / '7  OH 7  -,,  N. .\*-13 .. or .  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 wherein, within the proviso each R6, R7 and R8 independently represents 0 OH 0 0 0 0 0 0 OH  HO 0:,,,N -riss. oWc,  OH OH , 0  HO  OH 0 OH 0  o o -ss536 (j-el NOH = H 0 OH 0 (5H  t-Z<OH 1 NIE)  \WO HO 0 RH2  .., \\,/ 14 /17 ct.  t4 \ / \ s=!: A  A 11.\ "  A. \¨ /  .\3'''' A \' '5,"--t=j \-rt="1$ ;-''¨ $ \ ir. i -  0 ,  NNZ ¨NZ Nf/- NNZNZN\Z\NZ4 /  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  OH  Sr<1.0(Y2  NN,e7NN,-7µ'NNVI  NNZ ="' \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ =-=\  Ca' ,  HO sSS  JS  0 OH 0 0 0 )??2. 0  H 0 cs  HOWOH HOWOH 0 sftflAr OH  0 0 0 ??? 0  HOWOH0 -WOH 0 avvv, OH 0 OH 0 OH  HOW, csS5 µWOH  OH OH  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  , H 0yyci CSCOH  OH , 0 H 0 OH  `21LW H  0 OH  tss5 ; 0 OH or OH within the proviso; n = 0 to 80.  Ri represents null,  0\_ 121%1/4  LZ22\_cs-SS \L. 0 ssS 1/40  Wcsss. H o)c)21 sS5c)N \o  NH2  (221)\o/Q\sss Ac)N or \tõ r=J'cr  R2 represents  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 0 o 0  H 2 N  HWssss. L2z2,> ("a2(  XesS 0 s----S  (k. 5 11 14 17 20  rijµr,  NH2 0 N OH  N+ SO S .,%%%\ --......,..õ,.."(222\_. n = 0 - 40 , ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  H2N , H2 , .cS  OH  OH H2 ,  HO  OH 0  Nr.sSr 0 or  3. A compound of formula III j RH  HN  Formula III and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof wherein  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acidõ myristic acid, myristoleic acid, palmitoleic acidõ elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  Br  Br H  HOOH  N OH  OH 0  NH  HN OH  OH  OH  OH  H3N-; xµ OH 0  NH  OH /4'4.  H2N  HOOH 0 OH %, A  N OH  NN NH2  OH  NH2 OH  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  NOH 1 i\IFi3  N N. \ 1 L OH  N' N H3 S  OH  CI  NH2  H H  I)  WOH N N  H2N N NH2 1  F F CI 0 CI 0  NH2 H H2  N N + WOH H3N y.....=> H NI., N H2  F F CI  NH2 0  NH  OH  H2N NOH H2NN  NH  N` H3 0  H2N N H2 OH 1 H3N+ N OH  N1+  HO 1 0  CA 03149128 2022-01-28  WO 2021/019350 PC T/IB2020/056687  Fl cl  H H  HO  OE /  HO  HN  H3 cl  + ,  HO N  =-=N,,,,,,õ.,zr,õ-oC)H 1 HNL.)  W / /  \_0! 0 H3N+  N OH \*s OH  H =.  OH H2  H2N HS .\*\_\_ ==12 ,  OH OH  HS \*..i3  OH 0 ¨P a . or wherein, within the proviso each R6, R7 and R8 independently represents o OH 0 0 0 0 0 OH 0 0  HOHcr  HO ,Prrr oWissS  OH OH  HO  OH 0 OH 0 , ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  0 0 (D¨f NOH 0 OH 0 81-1  4-1-LzI,W 0 ITH2  \SF \\,/,  õrs.s.  N-NZNN/V---N7N7N--,"  ,it OH / 0 H  7NN.,===`  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  -N4o  HO csSS  ,OH  HO 0 (1) 0 0 )???. 0 cs5  HOWOH HOWOH 0 .11.11AP OH  0 0 \css.S  HOWOH EWOH  O JVV1P OH  OOH 0 OH  HOW, csSS LZ2zsW  OH  OH OH  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  OO awcsss HOrYc.C. CSCSOH  OH , 0 H 0 OH  µ22a,WOH 0 OH  csssa 0 0 OH iSSS8 or OH ; within the proviso; n = 0 to 80.  4. A compound of formula IV  RH  H2N+  Formula IV and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof; wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  Br  OH  Br  H H2  1 ...`,.....C......) õ.........N.......õ.  N N HOOH  NOH 0 =. ......õ/õ........,,OH HN ....\_ 7.....õ..1,µ,...................7,...  OH  OH  OH 1-If\'10H 0  H3N+4 .........1,.... OH NH  OH )----- ''.::\*-= 0 /J,4. .sto0 "..'/.............\- .........../....... H 2+ ...=  HOOH -, 0 OH  N OH  N======="----' ......:<.../..........",N \ ............................75...........¨....................õ,..--1 NH2 1 OH .--------S  NH2 OH , ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  NOH 1 i\lEi3  N N. \ 1 L OH  N NH3 S  OH  CI  NH2  H H  W OH N  H2N N T N NH2 1  F F CI 0 CI 0  NH2 H H2  N N + W H3N OH ID H -N-1 N H2  F F CI  NH2 0  NH  OH  H2N N OH H2N N  NH  N` H3 0  H2N N H2 OH 1 H3N+ N OH  N1+  HO 1 0  H CI  H H / N 101 N N  HO /  HN  HO  + CI ,  W , ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  HO N  HNJ N OH  OH  0 OH 0  H3N+  H2 OH , ,  H2N HS  OH H OH  NH2 2  HS.i3 ( 0 -R7  OH  R6-0 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ or wherein, within the proviso each R6, R7 and R8 independently represents 0 OH 0 0 0 OH 0 0 0 0  HO CDHO\/.sss o OH 0 OH , ,  HO ^5.50H 0 OH 0 , ,  ,SS5S(5 (j.sss,5 0 OH 0  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  NOH 4-4<.=OH i H  1 i\11E) \WO: H  5H 0  HO'S. ,A, / --- .., 1711-12 Ct. -, - 1  liN / , ''''\=,,VNN.,-",""'N.,-,""N",y;\  =",.`)  IL  CA 03149128 2022-01-28  WO 2021/019350 o PCT/IB2020/056687  HO 0 sgSS  0 OH 0 0 0 0  H 0 csss  HOWOH H OW OH 0 JVVV` OH  0 0  o- 0 .............,%.... cs  Cj HOWOH OWOH  O JNAAP OH , ,  0 OH  OH  HOW, sSS LZ2LWOH  OH OH  O c)o 0 0 0 csSC CSSS  OH 5WcsSS  OH 0 OH 0 OH , HO  ocsss ,zzLwOH  O OH 0 6.  csss 8 0 o o o H cssss 8 or oH ;  within the proviso;  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 n = 0 to 80.  5. A compound of formula V  CI  HN  RH  Formula V and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof; wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  Br  OH  Br  H H2  N N N H H H OH 0 N N 2 /444. .'",...T./ N 1 1 I-\_\_\_\_>  OH  N HO N 0 , ,  N 0H ).\_\_\_\_\_ 0 1 NH  OH  OH  OH\*\_--OH  Hf\'10H o  H N+ 0 1 OH  OH µ  H2N .=sssµµµµOH  HOOH  0 OH 1:\_--N OH  N N'''. NH  1 OH  L--S  NH2 OH  N OH  1 L OH  N NH3 S  OH  CI  NH2  H H  H2N W N OH N NH2  F F CI 0 CI 0  NH2  H H2  J. N N  H3 N OH D+ H N+1 N H2  F F CI  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  NH2 0  NH  H2N N OH ......,........,, ,.....,....,õ..,...,,,.,,OH  H2N N  NH  N' H3 0 1 + OH  H2N N H2 OH H3N N  N1+  HO 1 0  Fl CI  H H / N  N N  HO  OE / . \--.------\_\_\_)  HO  OE  H3 cl  + ,  0 OH  W , '  HO N  HNI..j  N OH  OH  \_NI0  H3N 0 OH+  H2 OH , ,  HS  OH  OH  H2N\*%'....%''....'--.'-.'%........-'-..%%\*\*I-Tj-12......-.....'''''''...Y........H2 ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  HS  OH /  NH3 + or , wherein, within the proviso each R6, R7 and R8 independently represents 0 OH  0 OH  HOr.....A.rr CDHOS. ,Prrr 5Wr5sS  OH 0 OH  , ,  HO  OH  o o -5-5548 ()-5,5 N OH  0 OH 0 ()H  (17,01-1 CS5S  E N  o 5H ,  \WO HO  , ,  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  /N.  OH c-5j-  Sr-<10r12  N'-=\,./VN= .=-= = -===== =-=.=="..., = -==== ./FN, =-"N,  HO ss$5 f=d  0 OH 0 0 0 ?. 0  HOWOH H OH  O OH  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 0 Oö o o o A  HOWOH 5 0 H 0 %NW OH 0 OH 0 OH  HOW-S5 cs.S5 µZ2.t.W 0 H  H n OH  H 0csS5 CSS5OH 5WcsSS  OH 0 OH 0 OH  aZa.W H 0 OH sssso csssso 0 OH or OH ; within the proviso; n = 0 to 80.  6. A compound of formula VI  RH  Ri¨R2  Formula VI and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  Br  OH  H H2 Br  N 0 N N H H H2N11/4 kOH  N N õ  N N HOOH  NOH O 0 1 OH ===ssµµµµ HN OH  OH  H-IVOH 0 1  H3N OH 0H 0 +, sk NH .." ..\.....õ.............  HN OH  HOOH 0 OH . s -..-=\_.--  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  N OH  N N='-'-'\_\_\_\_\_\_\_\\_\_\_ NH2 1 OH \-----S  NH2 OH  N OH 1 IV H 1 L OH  NNH3 S  OH  CI  NH2  H H  WOH N  H2N IN) N1 NH2  F F CI 0 CI 0  NH2 H H2  + OH +  H3NW HRI NH2  N i..) 1  F F CI  NH2 0  NH  OH  H2NN\*.12 .0H, H2NN,/  NH  NH3 0 + N OH  H2N N H2 OH 1 H3N  N+  HO 1 0  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  Fl cl  H H / N N N  HO /  HO  HN  H3 C l  17.) ,, 0..s.-.,,-,' o OH  YI  HO N 11 OH  OH  \_\_\_\_\_\_\_\_ 0 0 OH H3N+ : OH  H2N HS  OH OH  NH2 , \*-- .12 ,  HS ( \_\_\_\_\_ 0 ¨R7  OH  R6-0 \_\_  NH3 + or wherein, within the proviso each R6, R7 and R8 independently represents  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687 0 OH 0 0 0 OH 0 0 0 0  HO 0HO 'rrrr 5Wr, 0 OH OH  HO  OH 0 OH 0  o o -5553.0 CesS cgi E N  H OH 0 OH 0  II<W'OH cCS5 N HO  0 HO  0 FIH2  \VA 1 A \,,/ 14 \õ/17 \ /20 ,.  ts' \ s\\¨ / \\\* 1.\\ A  0 ,  sl  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  CrssS H 0 ss5  H 0 cs  HOWOH HOWOH 0 OH  VVVV`  H OW OH 5W OH 0 vvvv, OH 0 OH 0 OH  HOW/ ssSS tZaLWOH  OH  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  0 0 o 0 , HOr))15 CSCCOH aW  ,..., 1 c)- `21LWOH  0 OH 0  SSS5(5 0 ,,s a ; 0 OH or OH  within the proviso; n = 0 to 80;  Ri represents null,  "Inn,  0 0  c;22z,WcS5 ..-.----\ (õ.6.1.1õ.r. c2e) ¨\¨N sjj. ( H N H20 \ 0 ,  ).\  o N  f`risr  R2 represents  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  H2N 0 HO sis5s. (222,  NesS S 0 ¨......,  taz2..  t'2??¨ 5 11 14 17 20  fJsrr  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  NH2  c)  N )2;.= H OH S 0 SO's sµ  La2z,n ¨ 0 - 40 oLa22\_  H2N,  H 2 , ,ssLo  OH  OH NH2,  HO  OH 0  N+  or  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  7. A compound of formula vil  ¨re 0  RH  0 OH  Formula VII and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2,  I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2hydroxyethanesulfonic acid, 2oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  Br  OH  Br  H H2  N N N H H H2N11 ,,.,,,N,,,, N N1.> 14,õ  L.  0 N HOOH  N ,  N ...--, .0H O 0  OH  OH 1.' s  OH \*..../ I I  OH  HItl OH 0 0  H N+ OH NH ,,,,,,,,..........:5:õ.õ,............./ õ,......1 OH -: \\ ..,õ.%  H2N OH  HOOH -...\_ s 0 OH -.---- ,  N OH  N N ,....,...,,..,..,.....,./.--..,...,õ..õ..,..1  NH2 '''''\_\_\_\_\_\_\_\\_\_\_\_\_\_ 1 OH  NH2 OH  N OH  1 L OH  N NH3 S  OH  CI  NH2  H H  H2N W N OH T.\_ N NH2 1  F F CI , , 0 CI 0  NH2 H H2  N N  H IV W OH 3 1:1) H N+1 N H2  F F CI , ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  NH2 0  NH  OH  H2NN OH Fi2NN  NH  N'H3 0 1 + OH  H2N N H2 OH H3N N  N1+  HO 1 0  Fl cl  H H / N  HO  OE /  HOOE 101 N Y-\_\_)  H3 cl  + ,  (:) OH  HO N  HN,....)  N OH  OH  \_NI  0 OH 0  H3N+  H2 OH  HS  OH  OH  H2N\*%'....%'''......'%....%%'-\*/"...-'-..%%\*\*I-Tj12......'.....'''''''....Y..........H2 ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  HS ( \_\_\_\_ 0 ¨R7  OH  R6,---0 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  NH3 or wherein, within the proviso each R6, R7 and R8 independently represents  OH  0 0 0 0 OH 0 0  HO yrr  HOS. 5Wr5sS  OH 0 OH  HO  OH 0 OH 0  -ssjs(7) 0 OH 0  µl<W O  OH H  NE) 4111/4,W,  HO  CA 03149128 2022-01-28  WO 2021/019350  PCT/IB2020/056687  3 6. 9 12 15 18.  OH (-. ? ,  N..., "."\-\ \_FN. õ."...õ." \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ -,,,., õ."=,-, ,\_", ,,,N. ,' õ.5  N.."' =-=,/ -,.., N..../ N-," --,,, --,,,-- N.,"  Ne sC  Cr.................õ/"....../ H 0 c.s.55  H I's.s5S  0 OH 0 0 0 A. 0  H0 ....................................,........ cs  CS' HOWOH HOW OH 0 avvv, OH , ,  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  o o o )222. o  HOWOH OWOH  O avvv= OH 0 OH 0 OH  HOW/ cs-S5 µZ2.e.WOH  OH n OH  I-1 555 csssOH 5WcsSS  OH  OH 0 OH 0 OH  0 OH 0 sssso  OH ; 0 OH or within the proviso; n = 0 to 80.  8. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.  9. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable carrier.  10. A pharmaceutical composition comprising a compound of claim 3, and a pharmaceutically acceptable carrier.  11. A pharmaceutical composition comprising a compound of claim 4, and a pharmaceutically acceptable carrier.  12. A pharmaceutical composition comprising a compound of claim 5, and a pharmaceutically acceptable carrier.  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  13. A pharmaceutical composition comprising a compound of claim 6, and a pharmaceutically acceptable carrier.  14. A pharmaceutical composition comprising a compound of claim 7, and a pharmaceutically acceptable carrier.  15. The pharmaceutically composition of claim 8, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  16. The pharmaceutically composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  17. The pharmaceutically composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  18. The pharmaceutically composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  19. The pharmaceutically composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  20. The pharmaceutically composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  21. The pharmaceutically composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  22. The pharmaceutical compound of claim 15, and compound of claim 1, are formulated for the treatment of anal and rectal disorders.  23. The pharmaceutical compound of claim 16, and compound of claim 2, are formulated for the treatment of anal and rectal disorders.  24. The pharmaceutical compound of claim 17, and compound of claim 3, are formulated for the treatment of anal and rectal disorders.  25. The pharmaceutical compound of claim 18, and compound of claim 4, are formulated for the treatment of anal and rectal disorders.  26. The pharmaceutical compound of claim 19, and compound of claim 5, are formulated for the treatment of anal and rectal disorders.  27. The pharmaceutical compound of claim 20, and compound of claim 6, are formulated for the treatment of anal and rectal disorders.  28. The pharmaceutical compound of claim 21, and compound of claim 7, are formulated for the treatment of anal and rectal disorders.  29. A compound of the structure:  HO  (7)  Formula I Formula IV  CA 03149128 2022-01-28  WO 2021/019350 PCT/IB2020/056687  S sj.so - u A,,e ill  Formula VII Formula I  0 ¨& ¨N---N0 / ,c) (10 HNi  Formula VI Formula I  S ss.-L  SO 0 o eV¨  / , 0 c NI  Formula I Formula VI | for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermaladministration, spray, injection or other known formulation in the art. |  |
| 98 | **WO2021019350** | 2021 |  | 1. A compound of formula I    or a pharmaceutical acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, l-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1, 5 -disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,      wherein, within the proviso  each R6, R7 and R8 independently represents        within the proviso; n = 0 to 80.  R1 represents null,    2. A compound of formula II    and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, l-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1, 5 -disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, , myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,    wherein, within the proviso  each R6, R7 and R8 independently represents       within the proviso; n = 0 to 80.  R1 represents null,    R2 represents     and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, I-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2- oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid  (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1, 5 -disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, , myristic acid, myristoleic acid, palmitoleic acid, , elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,        wherein, within the proviso  each R6, R7 and R8 independently represents         within the proviso;  n = 0 to 80.  4. A compound of formula IV    and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof;  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, l-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2- oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid  (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1, 5 -disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,        wherein, within the proviso  each R6, R7 and R8 independently represents        within the proviso; n = 0 to 80.  5. A compound of formula V    and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof;  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, l-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,      wherein, within the proviso  each R6, R7 and R8 independently represents        within the proviso;  n = 0 to 80.  6. A compound of formula VI    and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, l-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2- oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene- 1, 5 -disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,        wherein, within the proviso  each R6, R7 and R8 independently represents      within the proviso; n = 0 to 80;  R1 represents null,    R2 represents       7. A compound of formula VII    and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, stereoisomers and derivatives thereof  wherein,  RH independently represents  NULL, Cl-, Na+, pyridoxine, R-lipoic acid, methyl cellulose, glutamic acid, aspartic acid, valproic acid, prostaglandin F2a , dopamine, morphine, loperamide, b-blockers, sodium valproate, codeine phosphate, N-acetyl cysteine, cysteine, 5-Hydroxytryptamine, Zn+2, Mg+2, Mn+2, l-, Ag+2, Na, K, mesalamine, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1, 5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid,      wherein, within the proviso  each R6, R7 and R8 independently represents        within the proviso;  n = 0 to 80.  8. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.  9. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable carrier.  10. A pharmaceutical composition comprising a compound of claim 3, and a pharmaceutically acceptable carrier.  11. A pharmaceutical composition comprising a compound of claim 4, and a pharmaceutically acceptable carrier.  12. A pharmaceutical composition comprising a compound of claim 5, and a pharmaceutically acceptable carrier.  13. A pharmaceutical composition comprising a compound of claim 6, and a pharmaceutically acceptable carrier.  14. A pharmaceutical composition comprising a compound of claim 7, and a pharmaceutically acceptable carrier.  15. The pharmaceutically composition of claim 8, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  16. The pharmaceutically composition of claim 9, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  17. The pharmaceutically composition of claim 10, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  18. The pharmaceutically composition of claim 11, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  19. The pharmaceutically composition of claim 12, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  20. The pharmaceutically composition of claim 13, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  21. The pharmaceutically composition of claim 14, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, rectal administration, buccal administration, subdermal administration, parenteral administration, systemic administration, delayed or sustained release administration or transdermal administration.  22. The pharmaceutical compound of claim 15, and compound of claim 1, are formulated for the treatment of anal and rectal disorders.  23. The pharmaceutical compound of claim 16, and compound of claim 2, are formulated for the treatment of anal and rectal disorders.  24. The pharmaceutical compound of claim 17, and compound of claim 3, are formulated for the treatment of anal and rectal disorders.  25. The pharmaceutical compound of claim 18, and compound of claim 4, are formulated for the treatment of anal and rectal disorders.  26. The pharmaceutical compound of claim 19, and compound of claim 5, are formulated for the treatment of anal and rectal disorders.  27. The pharmaceutical compound of claim 20, and compound of claim 6, are formulated for the treatment of anal and rectal disorders.  28. The pharmaceutical compound of claim 21, and compound of claim 7, are formulated for the treatment of anal and rectal disorders.  29. A compound of the structure: | for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermaladministration, spray, injection or other known formulation in the art. |  |
| 99 | **IN202147002301** | 2021 |  |  | treatment of eye diseases may be formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD. |  |
| 100 | **NZ771908** | 2021 |  |  | treatment of eye diseases may be formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD. |  |
| 101 | **NZ772282** |  |  |  | These conjugates may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of cancer or its associated complications. |  |
| 102 | **SG11202012473U** | 2021 |  |  | for the treatment of eye diseases may be formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, presbyopia, IOP, cataract, dry eye and oGVHD. |  |
| 103 | **RU0002749398** | 2021 |  | ​Claims   1.  ​Compound of Formula VI,  2.    3.  ​Formula VI,  4.  ​wherein  5.  ​RH is  6.  ;  7.  ​wherein R1 is  8.  ​or  ,  9.  ​while R2 and R3 are independently  10.  ​or  .  11.  2. ​A pharmaceutical composition for the treatment of pain comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.  12.  3. ​The pharmaceutical composition of claim 2, which is formulated for oral administration, delayed or sustained release, transmucosal administration, in the form of syrup, topical, parenteral administration, injection, subcutaneous, oral solution, rectal administration, transbuccal administration, or transdermal administration.  13.  4. ​The pharmaceutical composition of claim 3, wherein the pain is selected from chronic pain, pain associated with surgery, pain associated with cancer, pain associated with ulcer, neuropathic pain, pain as a result of damage to the nerve of the central and peripheral nervous system.  14.  5. ​The compound of claim 1, wherein the compound of claim 1 is selected from the group consisting of:  15.  ​or  . | useful for pain treatment, where pain is selected from chronic pain, have been obtained. pain associated with surgery pain associated with injury pain. associated with ulcer, neuropathic pain, pain resulting from damage to the nerve of the central and peripheral nervous system. 2 n and c c.p. f-ly, 6 ill., 3 pr. Formula VI |  |
| 104 | **EP3761970** | 2021 |  |  | treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases. |  |
| 105 | **IN202147000040** | 2021 |  |  | treatment of inflammatory skin diseases and cancer may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of facial hirsutism, GI Polyps, rosacea, acne, melanoma, psoriasis, dermatitis and cancer including gliomas, gastrointestinal polyps, anaplastic astrocytoma and metastatic cancers. |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |